Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status Prescription; Discontinued
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code Not Available
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Capillary fragility increasedC-C motif chemokine 2P14844Not Available26156105
Capillary fragility increasedInterleukin-1 alphaP01583T1634026156105
Capillary fragility increasedInterleukin-10P29456Not Available26156105
Metabolic disorderCytochrome P450 2C9P11712T192449663807; 11434505; 9825828
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinusitis22.07.03.007; 11.01.13.005--
Skin cancer23.08.02.002; 16.03.02.0020.000049%Not Available
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin fissures23.03.03.0080.000049%Not Available
Skin irritation23.03.04.0090.000049%Not Available
Skin odour abnormal23.03.03.0120.000049%
Skin reaction23.03.03.013; 10.01.03.0190.000073%Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.003--Not Available
Spinal fracture15.08.05.001; 12.04.04.0020.000025%
Status epilepticus17.12.03.005--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Stress19.06.02.004--Not Available
Subarachnoid haemorrhage17.08.01.010; 12.01.10.011; 24.07.04.004--Not Available
Subcutaneous abscess23.09.04.003; 11.01.12.0070.000049%Not Available
Suicidal ideation19.12.01.003--
Supraventricular tachycardia02.03.03.0120.000073%
Swelling08.01.03.015--Not Available
Swelling face23.04.01.018; 10.01.05.018--Not Available
Swollen tongue07.14.02.003; 23.04.01.014; 10.01.05.015--Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.0040.000049%Not Available
Tachycardia02.03.02.007--Not Available
Tendon rupture15.07.01.008; 12.01.07.0030.000049%Not Available
Tendonitis12.01.07.007; 15.07.01.0030.000049%Not Available
Tension19.06.02.005--Not Available
Throat irritation22.02.05.013; 07.05.03.004--Not Available
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 19 Pages